Dermatología en Costa Rica

Tuesday, April 23, 2019

Wide Local Excision Prior to Sentinel Lymph Node Biopsy for Primary Melanoma of the Head and Neck | PracticeUpdate

Published in Dermatology

Journal Scan / Research · April 22, 2019

Wide Local Excision Prior to Sentinel Lymph Node Biopsy for Primary Melanoma of the Head and Neck

International Journal of Dermatology

TAKE-HOME MESSAGE

http://www.practiceupdate.com/content/wide-local-excision-prior-to-sentinel-lymph-node-biopsy-for-primary-melanoma-of-the-head-and-neck/82261


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Comparison of Betamethasone Oral Mini-Pulse Therapy With Oral Azathioprine in Progressive Non-Segmental Vitiligo | PracticeUpdate

Published in Dermatology

Journal Scan / Research · April 22, 2019

Comparison of Betamethasone Oral Mini-Pulse Therapy With Oral Azathioprine in Progressive Non-Segmental Vitiligo

Journal of the American Academy of Dermatology

TAKE-HOME MESSAGE

http://www.practiceupdate.com/content/comparison-of-betamethasone-oral-mini-pulse-therapy-with-oral-azathioprine-in-progressive-non-segmental-vitiligo/81552


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Thursday, April 11, 2019

Estudio compara PRP mas minoxidil vs Minoxidil

MARZO 8, 2019

Platelet-Rich Plasma May Be Effective Therapy for Preventing Hair Loss

By Marielle Fares, PharmD

Washington, DC -- March 8, 2019 -- Treatment with platelet-rich plasma (PRP) is significantly more effective than topical minoxidil in women with androgenic alopecia (AGA), according to results of a study presented here at the 2019 Annual Meeting of the American Academy of Dermatology (AAD).

Alison Bruce, MB, ChB, Mayo Clinic, Jacksonville, Florida, presented the study on March 2.

Dr. Bruce and colleagues randomised 20 women to receive either PRP followed by minoxidil (arm A) or minoxidil followed by PRP (arm B).

Patients randomised to arm A received injections of PRP every 4 weeks, for a total of 3 treatments over 12 weeks. Patients then had a 2-month washout period, lasting until the end of month 4. Starting with month 5, they received crossover treatment with minoxidil by applying the 5% foam once daily for 3 months, and were then followed until 48 weeks after enrolment.

Patients in arm B used minoxidil topical foam for 3 months, followed by a 2-month washout period. They then received crossover treatment with PRP harvested and administered in the same manner as for the patients in arm A. At the end of PRP treatment, patients in arm B were also followed until 48 weeks after enrolment.

After 12 weeks, a trichoscan analysis in the PRP-treated patients showed significant increases from baseline in hair count (P = .002) and vellus hair density (P = .009) but no dramatic changes between baseline and 12 weeks regarding terminal hair density and cumulative thickness. The researchers also observed significant improvements with minoxidil treatment at 12 weeks in hair count (P< .001), vellus hair density (P = .030), terminal hair density (P = .004), and cumulative thickness (P = .004).

Correspondingly, there was a greater degree of improvement between baseline and week 12 for minoxidil than for PRP in hair count (= .009), terminal hair density (P = .003), and cumulative thickness (P = .005).

Interestingly, significant improvements in quality-of-life responses from baseline to week 12 were observed with PRP but not with minoxidil.

Although not superior to minoxidil, PRP treatment still may be effective for treating hair loss, particularly because of its novel method of action. Dr. Bruce highlighted the improved quality of life and treatment satisfaction in patients with PRP treatment compared with those on minoxidil treatment. These results suggest a trend toward possible benefit with combination therapy.

Further studies, conducted on a larger sample size, will be required to investigate the timing and frequency of PRP and possible effects when used in combination.

AGA is a hair loss disorder that negatively affects quality of life. PRPs are derived from whole autologous blood products that, when injected, are believed to activate growth factors, which in turn stimulate hair follicles. Previous studies have pointed to the safety and effectiveness of PRP in the treatment for AGA, but studies in women are lacking.

[Presentation title: A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women. Abstract 8520]


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Clasificación de riesgo en Alopecia Areata


Published in Dermatology

Journal Scan / Research · April 10, 2019

Topographic Phenotypes of Alopecia Areata and Development of a Prognostic Prediction Model and Grading System

JAMA Dermatology

IMPORTANCE

Diverse assessment tools and classification have been used for alopecia areata; however, their prognostic values are limited.

OBJECTIVE

To identify the topographic phenotypes of alopecia areata using cluster analysis and to establish a prediction model and grading system for stratifying prognoses.

DESIGN, SETTING, AND PARTICIPANTS

A retrospective cohort study of 321 patients with alopecia areata who visited a single tertiary referral center between October 2012 and February 2017 and underwent 4-view photographic assessment.

EXPOSURES

Clinical photographs were reviewed to evaluate hair loss using the Severity of Alopecia Tool 2. Topographic phenotypes of alopecia areata were identified using hierarchical clustering with Ward's method. Differences in clinical characteristics and prognosis were compared across the clusters. The model was evaluated for its performance, accuracy, and interobserver reliability by comparison to conventional methods.

MAIN OUTCOMES AND MEASURES

Topographic phenotypes of alopecia areata and their major (60%-89%) and complete regrowth probabilities (90%-100%) within 12 months.

RESULTS

A total of 321 patients were clustered into 5 subgroups. Grade 1 (n = 200; major regrowth, 93.4%; complete regrowth, 65.2%) indicated limited hair loss, whereas grades 2A (n = 66; major regrowth, 87.8%; complete regrowth, 64.2%) and 2B (n = 20; major regrowth, 73.3%; complete regrowth, 45.5%) exhibited greater hair loss than grade 1. The temporal area was predominantly involved in grade 2B, but not in grade 2A, despite being comparable in total extent of hair loss. Grade 3 (n = 20; major regrowth, 45.5%; complete regrowth, 25.5%) included diffuse or extensive alopecia areata, and grade 4 (n = 15; major regrowth, 28.2%; complete regrowth, 16.7%) corresponded to alopecia (sub)totalis. No significant differences in prognosis (hazard ratio [HR] for major regrowth, 0.79; 95% CI, 0.56-1.12) were found between grades 2A and 1, whereas grades 2B (HR, 0.41; 95% CI, 0.21-0.81), 3 (HR, 0.24; 95% CI, 0.12-0.50), and 4 (HR, 0.16; 95% CI, 0.06-0.39) had significantly poorer response. Among multiple models, the cluster solution had the greatest prognostic performance and accuracy. The tree model of the cluster solution was converted into the Topography-based Alopecia Areata Severity Tool (TOAST), which revealed an excellent interobserver reliability among 4 dermatologists (median quadratic-weighted κ, 0.89).

CONCLUSIONS AND RELEVANCE

Temporal area involvement should be independently measured for better prognostic stratification. The TOAST is an effective tool for describing the topographical characteristics and prognosis of hair loss and may enable clinicians to establish better treatment plans.

JAMA Dermatology

Topographic Phenotypes of Alopecia Areata and Development of a Prognostic Prediction Model and Grading System: A Cluster Analysis

JAMA Dermatol 2019 Mar 27;[EPub Ahead of Print], S Lee, BJ Kim, CH Lee, WS Lee 


TAKE-HOME MESSAGE



Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.

Friday, April 05, 2019

Hz y pso


 STORY OF THE WEEK
Published in Dermatology

Journal Scan / Consensus and Guidelines · April 04, 2019

Herpes Zoster Incidence and Consensus Recommendations on Vaccination in Adults on Systemic Therapy for Psoriasis or Psoriatic Arthritis

Journal of the American Academy of Dermatology

BACKGROUND

Herpes zoster (HZ) incidence is linked to immunosuppression. Patients with psoriasis (PsO) and/or psoriatic arthritis (PsA) on systemic therapy may be at increased risk for HZ.

OBJECTIVE

To assess HZ risk in patients with PsO/PsA by systemic treatment and provide recommendations regarding HZ vaccination.

METHODS

A systematic literature search was performed of HZ in patients with PsO/PsA. HZ vaccination guidelines were reviewed and the medical board of the National Psoriasis Foundation made consensus recommendations in PsO/PsA patients based on graded evidence.

RESULTS

41 studies met inclusion criteria. Systemic corticosteroids (strong, 1), tofacitinib (strong, 1), and combination therapy with biologic and conventional synthetic disease modifying antirheumatic drugs (weak, 2a) carry increased HZ risk while monotherapy does not. There is insufficient evidence to determine risk with interleukin 12/23, 17, and 23 inhibitors, or apremilast (weak, 2a). Recombinant zoster vaccine is recommended for all PsO/PsA patients >50 years old and to patients <50 years old on tofacitinib, systemic steroids, or combination systemic treatment. Vaccination of patients <50 years old on other systemic therapies may be considered on a case-by-case basis.

LIMITATIONS

There was significant heterogeneity between studies.

CONCLUSIONS

HZ risk depends on disease severity and treatment class. Recombinant zoster vaccine should be given to all PsO/PsA patients >50 years old and younger patients at increased risk.

TAKE-HOME MESSAGE


Journal of the American Academy of Dermatology
A Systematic Review of Herpes Zoster Incidence and Consensus Recommendations on Vaccination in Adult Patients on Systemic Therapy for Psoriasis or Psoriatic Arthritis: From the Medical Board of the National Psoriasis Foundation
J Am Acad Dermatol 2019 Mar 15;[EPub Ahead of Print], E Baumrin, A Van Voorhees, A Garg, SR Feldman, JF Merola 


Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.